8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Apr 2, 2026·SEC
Material company update
Dec 4, 2025·SEC
Palisade Bio, Inc.(PALI)Earnings, Financials & Key Ratios
PALI•NASDAQ
$1.89
Price updated Jun 27, 2026
AboutPalisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.Show more
- Revenue$0
- EBITDA-$18M-21.5%
- Net Income-$17M-16.2%
- EPS (Diluted)-0.30+97.1%
- ROE-24.52%+84.0%
PALI Price & Volume
Palisade Bio, Inc. (PALI) stock price & volume — 10-year historical chart
Loading chart...
Substantial Cash Reserves Offset Clinical Development Burn
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Contracting
Profitability:Negative
Financial Position:Healthy
Cash Flow:Burning
Primary Risk:Binary clinical trial failure
"Palisade Bio maintains a debt-free capital structure with $132.6 million in cash as of 2026Q1, providing a significant runway to advance its clinical pipeline despite the absence of recurring revenue. The company's reliance on external financing is evidenced by an accumulated deficit of $162.3 million, which necessitates successful clinical milestones to justify the current valuation. Investors should monitor the escalating R&D expenditure, which reached $6.4 million in 2026Q1, as the firm remains entirely dependent on its cash reserves to sustain operations."
Verdict Logic
while the $132.6 million cash position provides a strong liquidity buffer, the lack of revenue and the $10.7 million quarterly operating loss suggest significant execution risk remains.
PALI Growth Metrics
Palisade Bio, Inc. (PALI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-83.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM83.64%
Return on Capital
10 Years-889.29%
5 Years-423.58%
3 Years-96.58%
Last Year-26.29%
PALI Recent Earnings
Palisade Bio, Inc. (PALI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.05-25.0%
$0.04
Rev
—
—
Q2 2026
Mar 23, 2026Metric
Actual
Est
EPS
$0.04-100.0%
$0.02
Rev
—
—
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.38-18.8%
$0.32
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.58-20.8%
$0.48
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.05vs $0.04-25.0% | — |
| Q2 2026 | Mar 23, 2026 | $0.04vs $0.02-100.0% | — |
| Q4 2025 | Nov 10, 2025 | $0.38vs $0.32-18.8% | — |
| Q3 2025 | Aug 11, 2025 | $0.58vs $0.48-20.8% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Palisade Bio, Inc. (PALI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.89 | $396.26M | -6.30 | — | — | -24.52% | — | |
| $63.65 | $1.24B | -6.54 | -43.89% | -284.18% | -87% | — | |
| $74.96 | $8.89B | 29.28 | 37.55% | 23.13% | 126.27% | — | |
| $1.50 | $183.61M | -1.03 | -84.2% | -323.49% | -174.71% | — | |
| $10.02 | $524.58M | -2.21 | -92.84% | -260.92% | -49.88% | — | |
| $6.01 | $355.24M | -1.61 | 8.72% | -109.99% | -61.41% | — |
Compare PALI vs Peers
Palisade Bio, Inc. (PALI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PALI SEC Filings & Documents
Palisade Bio, Inc. (PALI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when PALI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PALI Frequently Asked Questions
Palisade Bio, Inc. (PALI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is PALI profitable?
Palisade Bio, Inc. (PALI) reported a net loss of $24.2M for fiscal year 2025.
Dividend & Returns
What is PALI's return on equity?
Palisade Bio, Inc. (PALI) has a return on equity (ROE) of -24.5%. Negative ROE indicates the company is unprofitable.
What is Palisade Bio, Inc.'s free cash flow?
Palisade Bio, Inc. (PALI) had negative free cash flow of $12.4M in fiscal year 2025, likely due to heavy capital investments.